XSHG
688068
Market cap2.48bUSD
Jul 31, Last price
195.00CNY
1D
2.66%
1Q
57.89%
IPO
324.10%
Name
Beijing Hotgen Biotech Co Ltd
Chart & Performance
P/E
650.90
P/S
32.93
EPS
0.30
Div Yield, %
0.10%
Shrs. gr., 5y
5.01%
Rev. gr., 5y
23.67%
Revenues
541m
-84.78%
Net income
27m
-97.10%
CFO
-25m
L
Dividend
Jul 03, 20240.2 CNY/sh
Profile
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. The company was founded in 2005 and is based in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 541,251 -84.78% | 3,556,552 -33.76% | ||||||
Cost of revenue | 553,673 | 2,257,846 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (12,422) | 1,298,705 | ||||||
NOPBT Margin | 36.52% | |||||||
Operating Taxes | (1,549) | 150,104 | ||||||
Tax Rate | 11.56% | |||||||
NOPAT | (10,873) | 1,148,602 | ||||||
Net income | 27,383 -97.10% | 944,737 -56.78% | ||||||
Dividends | (310,982) | |||||||
Dividend yield | 5.56% | |||||||
Proceeds from repurchase of equity | (16,444) | 32,290 | ||||||
BB yield | 0.45% | -0.58% | ||||||
| Debt | ||||||||
Debt current | 7,492 | 27,949 | ||||||
Long-term debt | 15,528 | 28,367 | ||||||
Deferred revenue | 9,767 | 10,775 | ||||||
Other long-term liabilities | 1 | 1 | ||||||
Net debt | (1,948,979) | (1,505,482) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (25,386) | 978,753 | ||||||
CAPEX | (413,356) | |||||||
Cash from investing activities | (161,867) | |||||||
Cash from financing activities | ||||||||
FCF | (405,338) | 842,778 | ||||||
| Balance | ||||||||
Cash | 552,411 | 1,412,178 | ||||||
Long term investments | 1,419,588 | 149,620 | ||||||
Excess cash | 1,944,936 | 1,383,970 | ||||||
Stockholders' equity | 3,111,271 | 3,091,655 | ||||||
Invested Capital | 1,438,117 | 2,007,368 | ||||||
ROIC | 77.27% | |||||||
ROCE | 38.19% | |||||||
| EV | ||||||||
Common stock shares outstanding | 88,332 | 91,900 | ||||||
Price | 41.10 -32.51% | 60.90 -22.40% | ||||||
Market cap | 3,630,448 -35.13% | 5,596,738 -22.53% | ||||||
EV | 1,681,469 | 4,109,715 | ||||||
EBITDA | 58,105 | 1,418,996 | ||||||
EV/EBITDA | 28.94 | 2.90 | ||||||
Interest | 1,120 | 2,318 | ||||||
Interest/NOPBT | 0.18% | |||||||